BEAM SEC Filings: 8-K, 10-Q, S-3 & 424B

Financials

TYPE

HEADLINE

FILED AT

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Nov 3, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Aug 4, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

May 7, 2026

10-K

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Feb 24, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Nov 4, 2025

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Aug 5, 2025

News

TYPE

HEADLINE

FILED AT

8-K

Beam Therapeutics Reports Q3 2026 Financial Results and Highlights Clinical Progress Across Base Editing Portfolio

Nov 3, 2026

8-K

Beam Therapeutics Reports Q2 2026 Financial Results and Clinical Pipeline Progress

Aug 4, 2026

8-K

Beam Therapeutics Inc. Announces Results of 2026 Annual Meeting of Stockholders

Jun 8, 2026

8-K

Beam Therapeutics Reports Q1 2026 Financial Results and Clinical Pipeline Progress

May 7, 2026

8-K

Beam Therapeutics Terminates License Agreement with Bio Palette; Standby License from Kobe University Activated

Mar 5, 2026

8-K

Beam Therapeutics Reports Q4 2025 Results, Announces New PKU Program (BEAM-304), and Secures Strategic Financing

Feb 24, 2026

Prospectus

TYPE

HEADLINE

FILED AT

424B5

Form 424B5 - Prospectus [Rule 424(b)(5)]

Mar 10, 2025

424B5

Form 424B5 - Prospectus [Rule 424(b)(5)]

Mar 10, 2025

424B5

ATM | Offering amount: $300,000,000 | Amount sold to date: $772,800,000

May 10, 2023

424B5

Common Stock-

Jul 7, 2021

424B5

Common Stock-

Apr 1, 2021

424B7

Form 424B7 - Prospectus [Rule 424(b)(7)]

Apr 1, 2021

Registrations

TYPE

HEADLINE

FILED AT

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

Feb 24, 2026

FWP

Form FWP - Filing under Securities Act Rules 163/433 of free writing prospectuses

Mar 10, 2025

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

Feb 25, 2025

S-3ASR

SHELF | ATM | Offering amount: $236,027,466.00

Feb 27, 2024

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

Feb 27, 2024

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

Feb 28, 2023

Proxies

TYPE

HEADLINE

FILED AT

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Apr 17, 2026

DEF 14A

Form DEF 14A - Other definitive proxy statements

Apr 17, 2026

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Apr 18, 2025

DEF 14A

Form DEF 14A - Other definitive proxy statements

Apr 18, 2025

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Apr 19, 2024

DEF 14A

Form DEF 14A - Other definitive proxy statements

Apr 19, 2024

Ownerships

TYPE

HEADLINE

FILED AT

Evans John M. (Reporting)

Oct 16, 2026

144

Form 144 - Report of proposed sale of securities

Oct 16, 2026

144

Form 144 - Report of proposed sale of securities

Oct 15, 2026

Cavanagh Bethany J (Reporting)

Oct 2, 2026

Ciaramella Giuseppe (Reporting)

Sep 25, 2026

SCHEDULE 13G/A

ARK Investment Management LLC (Filed by)

Aug 14, 2026

Other

TYPE

HEADLINE

FILED AT

LETTER

Form UPLOAD - SEC-generated letter

Oct 12, 2023

CORRESP

Form CORRESP - Correspondence

Sep 20, 2023

LETTER

Form UPLOAD - SEC-generated letter

Aug 22, 2023

CORRESP

Form CORRESP - Correspondence

Aug 9, 2023

LETTER

Form UPLOAD - SEC-generated letter

Jul 20, 2023

EFFECT

Form EFFECT - Notice of Effectiveness

Oct 1, 2020

Beam Therapeutics Inc. BEAM · SEC Filings